全球心肌肌鈣蛋白市場 - 2024-2031

心肌肌鈣蛋白市場規模

全球心肌肌鈣蛋白市場在 2023 年達到 41.9 億美元，預計到 2031 年將達到 95.6 億美元，2024-2031 年預測期間複合年成長率為 11.2%。

心肌肌鈣蛋白通常是檢測心肌損傷的測試。肌鈣蛋白是一種蛋白質，僅在心肌受損（如心臟病發作）時才會在血液中出現。肌鈣蛋白升高的其他原因也存在，但心臟病發作是最常見的。此測試不能測量血液中正常情況下的少量肌鈣蛋白。肌鈣蛋白 T 高度敏感 (hs-TnT)，已用於進階測試。

心肌肌鈣蛋白市場動態

全球心肌肌鈣蛋白市場的成長是由技術進步、人口老化、心血管疾病盛行率上升、患者意識提高以及患者醫療支出增加所推動的。

心血管疾病盛行率的增加推動了市場的成長

人們對心血管疾病和醫療基礎設施的認知不斷提高，推動了全球市場的發展。根據世界衛生組織（WHO）的數據，心血管疾病是全世界死亡的主要原因。每年約有 1790 萬人患有心血管疾病。五分之四以上的CVD 死亡是由於心臟病發作和中風造成的，其中三分之一的死亡發生在70 歲以下的人群中。發展。

心肌肌鈣蛋白是一種已確定的生物標記物，可以影響急性冠狀動脈綜合症患者護理的改變。肌鈣蛋白從受損的心肌釋放到血液中。新的高靈敏度血液檢測可以在症狀出現後立即檢測到非常低的肌鈣蛋白水平。心電圖 (ECG) 可測量心臟的電活動，並可顯示心臟病發作時的異常情況。

此外，市場參與者正在採取合作和產品發布等市場策略。例如，2022 年 6 月，LumiraDx Limited 宣布其產品組合多元化，其 D-二聚體測試和 NT-proBNP 測試獲得了 CE 標誌。後者預計於 2022 年底實現商業化，預計將有助於臨床決策。

與心肌肌鈣蛋白相關的副作用將阻礙市場的成長

然而，與心肌肌鈣蛋白或骨骼損傷等生物標記相關的有限特異性和副作用阻礙了市場的成長。

COVID-19對心肌肌鈣蛋白市場的影響分析

COVID-19 的影響對全球心肌肌鈣蛋白市場產生了重大影響。根據2021 年10 月發表在Nature Reviews Cardiology 上的文章，中度至重度COVID-19 患者的心血管併發症和心臟損傷的證據（肌鈣蛋白水平升高和左心室射血分數降低）。有心血管疾病的患者可能更容易出現心血管併發症。疾病的患者高出三倍。

此外，COVID-19 患者可能有發生心臟併發症的風險，尤其是急性心臟損傷和心律不整；急性心肌損傷在患有心血管疾病的患者中可能更常見，並且與發病率和死亡率增加有關。

另一方面，根據美國心臟學會的數據，2020 年，COVID-19 感染患者肌鈣蛋白結果異常的頻率和非特異性，建議臨床醫生僅在診斷​​為急性心肌梗塞時才測量肌鈣蛋白。環境中進行評估。如果沒有支持證據，肌鈣蛋白異常不應被認為是急性心肌梗塞的證據。

心肌肌鈣蛋白市場細分分析

預計在預測期內（2023-2030 年），即時檢測領域將以最快的複合年成長率成長

按類型：

肌鈣蛋白I

肌鈣蛋白T

其他

按測試地點：

實驗室測試

照護端測試

即時檢測領域佔據最大的市場佔有率。健康記錄即時檢測系統的日益普及預計將在預測期內提振市場。根據 2020 年 11 月在《實用實驗室醫學》上發表的文章，認證和監管標準凸顯了將 POC 測試結果整合到患者電子病歷中的需求不斷成長。這提高了 POCT 結果的可獲取性、監測和趨勢的能力、防止不必要的重複測試並為患者結果提供證據。

由於POCT 結果用於做出臨床決策，因此重要的是記錄結果以及相關參考區間、測量單位、臨界值（如果適用）、測試日期和時間，並且還可以追溯到設備序號、操作員識別號、試劑批號和品質控制 (QC) 結果。 POCT 結果也應與其他中心實驗室結果明確區分開來，以避免混淆和不同分析方法的結果趨勢。 POCT 目前已成為所有醫院的常規檢查，並已成為其他各種醫療機構中病患照護的標準。透過 POCT 可以準確地檢測心肌肌鈣蛋白。

按申請：

急性冠狀動脈綜合症

心肌梗塞

充血性心臟衰竭

其他

透過最終用戶：

醫院

診斷中心

心肌肌鈣蛋白市場地域佔有率

北美地區佔據全球心肌肌鈣蛋白市場最大的市場佔有率

按地區：

北美洲

拉丁美洲

歐洲

亞太地區

中東和非洲

北美在心肌肌鈣蛋白市場上佔據主導地位，預計在預測期內將呈現類似的趨勢。該市場是由心臟病診斷需求的增加和心臟生物標記的進步等因素所推動的。

根據疾病管制與預防中心的數據，2020 年，美國約有 2,010 萬名 20 歲及以上的成年人患有 CAD（約 7.2%）。心血管疾病患者的增加導致該地區市場的需求增加，從而推動了該地區的市場。

此外，市場參與者也在美國地區提供產品。例如，Quidel 公司提供 TriageTrueTM 高靈敏度肌鈣蛋白 I 測試，用於定量測定 EDTA 抗凝血全血和血漿樣本中的肌鈣蛋白 I。此測試將與 Quidel 的 Triage MeterPro 儀器系統一起使用，作為心肌梗塞 (MI) 診斷的輔助手段。

心肌肌鈣蛋白市場公司與競爭格局

心肌肌鈣蛋白市場是本地和全球公司競爭適度的市場。為市場成長做出貢獻的一些主要參與者包括 Biomerieux、Beckman Coulter、Siemens Healthcare、Roche、Fujirebio、Abbott、LifeSign、Alere 和 Singulex 等。主要參與者正在採取多種成長策略，例如產品發布、收購和合作，為全球心肌肌鈣蛋白市場的成長做出貢獻。

例如，

2021 年 4 月，羅氏宣布了兩種關鍵心臟生物標記 (cTnT-hs) 的一系列五種新預期用途，採用 Elecsys 技術，該技術具有 NT-proBNP 和高度敏感的心肌肌鈣蛋白 T。

生物梅里埃

概述 ：

生物梅里埃是法國跨國生物技術組織，成立於1963年，總部位於法國。它提供創新的產品和服務，以滿足全球解決方案的需求。

產品組合：

VIDAS 高敏感肌鈣蛋白 I：它對於最佳化急性冠狀動脈綜合症 (ACS) 的治療很有幫助。它為診斷和風險分層提供了高水準的性能，並在 2 小時內提供診斷。

全球心肌肌鈣蛋白市場報告將提供約 40 多個市場資料表、45 多個數字和 200（大約）頁數。

目錄

第 1 章：市場方法論與範圍

• 研究方法
• 報告的研究目的和範圍

第 2 章：市場定義與概述

第 3 章：執行摘要

第 4 章：市場動態

• 市場影響因素
  • 促進要素
    • 對診斷心血管疾病的心臟生物標記的需求不斷成長
    • 急性冠狀動脈綜合症盛行率上升
  • 限制：
    • 採集樣本缺乏所需的精度
  • 機會
  • 影響分析

第 5 章：產業分析

• 波特五力分析
• 供應鏈分析
• 監管分析

第 6 章：COVID-19 分析

第 7 章：按類型

• 肌鈣蛋白I
• 肌鈣蛋白T

第 8 章：按測試地點

• 實驗室測試
• 照護端測試

第 9 章：按申請

• 急性冠狀動脈綜合症
• 心肌梗塞
• 充血性心臟衰竭
• 其他

第 10 章：最終用戶

• 醫院
• 診斷中心
• 其他

第 11 章：按地區

• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 歐洲其他地區
• 南美洲
  • 巴西
  • 阿根廷
  • 南美洲其他地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 亞太地區其他地區
• 中東和非洲

第 12 章：競爭格局

• 主要進展和策略
• 公司股份分析
• 產品基準化分析

第 13 章：公司簡介

• Biomerieux
• 公司概況
• 產品組合和描述
• 主要亮點
• 財務概覽
• Beckman Coulter
• Siemens Healthcare
• Roche
• Fujirebio
• Abbott
• LifeSign
• Alere
• Singulex(*LIST NOT EXHAUSTIVE)

第 14 章：數據M

Cardiac Troponin Market Size

The Global Cardiac Troponin Market reached US$ 4.19 billion in 2023 and is expected to reach US$ 9.56 billion by 2031, growing at a CAGR of 11.2% during the forecast period 2024-2031.

Cardiac troponin generally is a test that detects damage to the heart muscle. Troponin is a protein that occurs in the blood only when the heart muscle is damaged, as in a heart attack. Other reasons for elevated troponin exist, but a heart attack is the most familiar. The test does not measure the low amounts of troponin normally in blood. Troponin T is highly sensitive (hs-TnT) and has been used for advanced tests.

Cardiac Troponin Market Dynamics

The global cardiac troponin market growth is driven by technological advancements, an increasingly aging population, a rising prevalence of cardiovascular patients, improving patient awareness, and rising patient healthcare expenditure.

An increasing prevalence of cardiovascular disease drives the market growth

The rising awareness of the cardiovascular disease and healthcare infrastructure drive the global market. As per the World Health Organization (WHO), cardiovascular disease is the leading cause of death worldwide. Each year around 17.9 million people suffer from cardiovascular disease. More than four of five CVD deaths are due to heart attacks and strokes, and one-third of these deaths happen prematurely in people under 70. Rising patients with the disease need to diagnose the disease drives the market.

Cardiac troponin is an identified biomarker that can impact a change in the care of a patient with acute coronary syndrome. Troponin protein is released from damaged heart muscle into the bloodstream. New high-sensitivity blood tests allow the detection of a very low troponin level soon after the onset of symptoms. The electrocardiogram (ECG) measures the heart's electrical activity and can show abnormalities in a heart attack.

In addition, the market players are adopting the market strategies such as collaboration and product launches. For instance, in June 2022, LumiraDx Limited announced the diversification of its portfolio with a CE Mark for its D-Dimer test and NT-proBNP test. The commercialization of the latter is projected by the end of 2022, which is expected to facilitate clinical decision-making.

The side effects associated with cardiac troponin will hamper the growth of the market

However, limited specificity and side effects associated with cardiac troponin or biomarkers such as skeletal injury hinder the market growth.

COVID-19 Impact Analysis on Cardiac Troponin Market

The impact of COVID-19 is significant effected on the global cardiac troponin market. As per the article published in Nature Reviews Cardiology in October 2021, cardiovascular complications in patients with moderate-to-severe COVID-19 and evidence of cardiac injury (elevated troponin levels and reduced left ventricular ejection fraction. Patients with preexisting cardiovascular disease may be more susceptible to COVID-19 infection. They may be at increased risk of death, especially when patients present with elevated troponin T levels, where mortality may be three-fold higher than those without cardiovascular disease patients.

Also, those with COVID-19 may be at risk of developing cardiac complications, especially acute cardiac injury and arrhythmias; acute myocardial injury may be more common in patients with preexisting cardiovascular disease and associated with increased morbidity and mortality.

On the other hand, according to the American College of Cardiology, in 2020, the frequency and non-specific nature of abnormal troponin results among patients with COVID-19 infection, clinicians are suggested to only measure troponin if the diagnosis of acute MI is being evaluated in clinical environments. Without supporting evidence, an abnormal troponin should not be supposed to be evidence for an acute MI.

Cardiac Troponin Market Segmentation Analysis

The point-of-care testing segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)

By Type:

Troponin I

Troponin T

Others

By Location of Testing:

Laboratory Testing

Point of Care Testing

The point of care testing segment accounts for the largest market share. The rising adoption of point-of-care testing systems for health records is expected to boost the market over the forecast period. As per the article published in Practical Laboratory Medicine in November 2020, Accreditation and regulatory standards highlight the rising need to integrate POC Testing results into the patient's electric medical records. This promotes accessibility of POCT results, the ability to monitor and trend, prevents unnecessary repeat testing and provides evidence for patient outcomes.

As POCT results are used to make clinical decisions, it is important to document results with associated reference intervals, units of measurement, critical values if applicable, date and time of testing, and also be traceable to device serial number, operator identification number, reagent lot number, and quality control (QC) results. POCT results should also be clearly differentiated from other central laboratory results to avoid confusion and trending results from different analytical methodologies. POCT is currently routine in all hospitals and has become the standard for patient care in a variety of other healthcare settings. Cardiac troponin is accurately performed by POCT.

By Application:

Acute Coronary Syndrome

Myocardial Infarction

Congestive Heart Failure

Others

By End User:

Hospitals

Diagnostic Centers

Cardiac Troponin Market Geographical Share

North America region holds the largest market share of the global cardiac troponin market

By Region:

North America

Latin America

Europe

Asia Pacific

Middle East and Africa

North America dominates the market for cardiac troponin and is expected to show a similar trend over the forecast period. The market is driven by the factors such as increasing demand for diagnosis of cardiac disease and advancements in cardiac biomarkers.

As per the Centers for Disease Control and Prevention, 2020, in the United States about 20.1 million adults age 20 and older have CAD (about 7.2%). The rising the patients with cardiovascular disease leads to increasing demand for the market in the region which drives the market in the region.

In addition, the market players are offers the products in the United States region. For instance, Quidel Corporation provides TriageTrueTM High Sensitivity Troponin I Test for the quantitative determination of troponin I in EDTA anticoagulated whole blood and plasma specimens. The test is to be indicated as an aid in the diagnosis of myocardial infarction (MI) for use with Quidel's Triage MeterPro instrumented system.

Cardiac Troponin Market Companies and Competitive Landscape

The cardiac troponin market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Biomerieux, Beckman Coulter, Siemens Healthcare, Roche, Fujirebio, Abbott, LifeSign, Alere, and Singulex, among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the cardiac troponin market globally.

For instance,

In April 2021, Roche announced a series of five new intended uses for two key cardiac biomarkers (cTnT-hs), using the Elecsys technology, which has the NT-proBNP and highly sensitive cardiac troponin T.

Biomerieux

Overview:

Biomerieux is a French multinational biotechnology organization founded in 1963 and headquartered in France. It offers innovative products and services to meet the need for global solutions.

Product Portfolio:

VIDAS High sensitive Troponin I: It is a useful aid to optimize the management of Acute Coronary Syndromes (ACS). It provides a high level of performance for diagnosis and risk stratification and delivers a diagnosis within 2 hours.

The global Cardiac Troponin market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising demand for cardiac biomarkers to diagnose cardiovascular diseases
    • 4.1.1.2. Rising prevalence of acute coronary syndrome
  • 4.1.2. Restraints:
    • 4.1.2.1. Lack of required precision for collecting samples
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Troponin I*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
• 7.3. Troponin T

8. By Location of Testing

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Location of Testing
  • 8.1.2. Market Attractiveness Index, By Location of Testing
• 8.2. Laboratory Testing*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
• 8.3. Point of Care Testing

9. By Application

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 9.1.2. Market Attractiveness Index, By Application
• 9.2. Acute Coronary Syndrome*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
• 9.3. Myocardial Infarction
• 9.4. Congestive Heart Failure
• 9.5. Others

10. By End User

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.1.2. Market Attractiveness Index, By End User
• 10.2. Hospitals*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
• 10.3. Diagnostic Centers
• 10.4. Others

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030, By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Location of Testing
  • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. The U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Location of Testing
  • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. U.K.
    • 11.3.7.3. France
    • 11.3.7.4. Italy
    • 11.3.7.5. Spain
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Location of Testing
  • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Location of Testing
  • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Location of Testing
  • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

• 12.1. Key Developments and Strategies
• 12.2. Company Share Analysis
• 12.3. Product Benchmarking

13. Company Profiles

• 13.1. Biomerieux*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Key Highlights
  • 13.1.4. Financial Overview
• 13.2. Beckman Coulter
• 13.3. Siemens Healthcare
• 13.4. Roche
• 13.5. Fujirebio
• 13.6. Abbott
• 13.7. LifeSign
• 13.8. Alere
• 13.9. Singulex(*LIST NOT EXHAUSTIVE)

14. DataM Intelligence

• 14.1. Appendix
• 14.2. About Us and Services
• 14.3. Contact Us